Coal tar
This article was originally published in The Tan Sheet
Executive Summary
FDA finds "no adequate basis to change the status of coal tar-containing drug products for the treatment of dandruff, seborrheic dermatitis and psoriasis from OTC to prescription or to require additional warning statements on product labeling," agency says in Feb. 22 response to Occupational Knowledge International's citizen petition seeking Rx-only sales of the ingredient. California Prop 65 litigation had been stayed pending FDA's determination
You may also be interested in...
OTC Coal Tar Skin Cancer Causation Data Lacking - FDA
The future of California Proposition 65 litigation against manufacturers, distributors and retailers of coal tar-containing dandruff shampoos, soaps and ointments could become clearer at a March 16 status conference in San Francisco state court.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC